Results 211 to 220 of about 360,147 (291)

Unveiling the Frontiers of Synthetic Biology in Brazil: Pioneering the National Synthetic Biology Network. [PDF]

ACS Omega
Santos LV, Maklouf GR, do Nascimento CZS, Lins MRCR, Rezende JC, Rojas CA, Sampaio Y, El Kadri NK, Kundlatsch GE, Simão RCG, Rech EL, Silva LF, Pedrolli DB.   +12 more
europepmc   +1 more source

PYCR1 inhibition in bone marrow stromal cells enhances bortezomib sensitivity in multiple myeloma cells by altering their metabolism

Molecular Oncology, EarlyView.
This study investigated how PYCR1 inhibition in bone marrow stromal cells (BMSCs) indirectly affects multiple myeloma (MM) cell metabolism and viability. Culturing MM cells in conditioned medium from PYCR1‐silenced BMSCs impaired oxidative phosphorylation and increased sensitivity to bortezomib.
Inge Oudaert, Lauren van den Broecke, Osman Aksoy, Judith Lind, Sonia Vallet, Arne Van der Vreken, Gamze Ates, Ann Massie, Ken Maes, Kim De Veirman, Elke De Bruyne, Karin Vanderkerken, Klaus Podar, Eline Menu   +13 more
wiley   +1 more source

Combination therapy dramatically promotes remyelination. [PDF]

J Mol Cell Biol
Li Y, Li P, Song Y, Zhang W, Jiang X, Chen S, Luo W, Ma C, Liu C, Niu J, Liang A, Du Y, Zhou BO, Zhang M.   +13 more
europepmc   +1 more source

Multi‐omic profiling of squamous cell lung cancer identifies metabolites and related genes associated with squamous cell carcinoma

Molecular Oncology, EarlyView.
Using multi‐omic characterization, we aimed to identify key regulators specific to squamous cell lung carcinoma (SqCC). SqCC‐specific differentially expressed genes were integrated with metabolics data. High expression of the creatine transporter SLC6A8, along with elevated creatine levels, appeared to be a distinct metabolic feature of SqCC.
Johan Staaf, Daniel Ehinger, Hans Brunnström, Mats Jönsson, Frida Rosengren, Marija Kotevska, Anna Karlsson, Mattias Aine, Christian Frezza, Maria Planck, Elsa Arbajian   +10 more
wiley   +1 more source

The Antarctic Wintering Alters the Properties of Human Plasma Cell-Free DNA. [PDF]

Biochem Res Int
Ponomarev S, Kotikova A, Osetsky N, Veiko N, Ershova E, Malinovskaya E, Savinova E, Chudakova J, Eliseeva J, Izhevskaia V, Kutsev S, Kostyuk S.   +11 more
europepmc   +1 more source

Inhibition of CDK9 enhances AML cell death induced by combined venetoclax and azacitidine

Molecular Oncology, EarlyView.
The CDK9 inhibitor AZD4573 downregulates c‐MYC and MCL‐1 to induce death of cytarabine (AraC)‐resistant AML cells. This enhances VEN + AZA‐induced cell death significantly more than any combination of two of the three drugs in AraC‐resistant AML cells.
Shuangshuang Wu, Jianlei Zhao, Aaban Asfar Azmi, Avanti Gupte, Jenna Thibodeau, Shuang Liu, Jinli Yang, Guan Wang, Holly Edwards, Lisa A. Polin, Juiwanna Kushner, Sijana H. Dzinic, Kathryn White, Julie Boerner, Maik Hüttemann, Jay Yang, Yue Wang, Jeffrey W. Taub, Yubin Ge   +18 more
wiley   +1 more source

A digital DNA system favours the superiority of unidirectional inheritance over 'Lamarckian' inheritance. [PDF]

PLoS Comput Biol
Shiju A, Arras SDM, Rodrigo AG, Poole AM.   +3 more
europepmc   +1 more source

A synthetic benzoxazine dimer derivative targets c‐Myc to inhibit colorectal cancer progression

Molecular Oncology, EarlyView.
Benzoxazine dimer derivatives bind to the bHLH‐LZ region of c‐Myc, disrupting c‐Myc/MAX complexes, which are evaluated from SAR analysis. This increases ubiquitination and reduces cellular c‐Myc. Impairing DNA repair mechanisms is shown through proteomic analysis.
Nicharat Sriratanasak, Bodee Nutho, Worawat Wattanathana, Narumon Phaonakrop, Bunnatut Panasawatwong, Katharina Erlenbach‐Wuensch, Sittiruk Roytrakul, Regine Schneider‐Stock, Pithi Chanvorachote   +8 more
wiley   +1 more source

Impact of substrate choice on human osteoclast differentiation and secretome: Implications for targeted therapeutic development. [PDF]

PLoS One
D'Amélio F, Vigerelli H, Araldi RP, da Costa Neves A, Prieto-da-Silva ÁRB, Pimenta D, Kerkis I.   +6 more
europepmc   +1 more source